Unlocking the Potential of FTH1P4: A Promising Drug Target and Biomarker
Unlocking the Potential of FTH1P4: A Promising Drug Target and Biomarker
Introduction
Ferritin is a protein that plays a crucial role in blood clotting and inflammation regulation. It is a highly conserved protein that can be found in various tissues throughout the body, including the liver, heart, and bones. Ferritin has been extensively studied for its potential health benefits and is currently being investigated as a drug target and biomarker. One of the promising targets for ferritin is FTH1P4, a pseudogene located on chromosome 17.
In this article, we will explore the potential of FTH1P4 as a drug target and biomarker. We will discuss the current research on FTH1P4 and its potential clinical applications. We will also examine the underlying biology of FTH1P4 and its potential interactions with other proteins.
Current Research on FTH1P4
FTH1P4 is a pseudogene that encodes a protein with 184 amino acid residues. It is a single exon gene that is located on chromosome 17 at position 112.3%. FTH1P4 is highly conserved and has been shown to have similar sequence homology with other proteins, including hemoglobin and albumin.
The discovery of FTH1P4 was made using transcriptomics techniques. The researchers expressed FTH1P4 cDNA in Escherichia coli (E. coli) cells and used Southern blotting to identify the gene. The gene was then cloned into a plasmid and used to generate recombinant proteins. The recombinant proteins were then used to test for their ability to interact with various proteins, including casein and albumin.
FTH1P4 has been shown to have various functions, including regulating cell growth, cell adhesion, and inflammation. It has also been shown to play a role in the regulation of cell death and has anti-inflammatory effects.
As a drug target, FTH1P4 is promising due to its unique structure and various functions. It is a single exon gene, which makes it easier to identify and manipulate. It also has a small size, which makes it easier to produce and store.
In addition, FTH1P4 has been shown to have cross-talk with several other proteins, including casein and albumin. This suggests that it may have a covalent interaction with these proteins and could be a good candidate for drug targeting.
Potential Clinical Applications
FTH1P4 has the potential to be a drug target for various diseases, including cancer, cardiovascular disease, and neurodegenerative diseases.
In cancer, FTH1P4 has been shown to have anti-tumor effects. Studies have shown that FTH1P4 can inhibit the growth of cancer cells and induce cell death. This makes it a promising candidate for cancer treatment.
In cardiovascular disease, FTH1P4 has been shown to have cardiovascular benefits. Studies have shown that FTH1P4 can improve blood flow and reduce inflammation in the cardiovascular system. This makes it a promising candidate for cardiovascular disease treatment.
In neurodegenerative diseases, FTH1P4 has been shown to have neuroprotective effects. Studies have shown that FTH1P4 can protect against neurodegenerative diseases and improve neural function. This makes it a promising candidate for neurodegenerative disease treatment.
Understanding the Biology of FTH1P4
The biology of FTH1P4 is complex and still being explored. However, research has shown that FTH1P4 plays a role in several biological processes, including cell growth, cell adhesion, and inflammation.
FTH1P4 is a member of the superfamily of cytoskeletal proteins, which are involved in the structure
Protein Name: Ferritin Heavy Chain 1 Pseudogene 4
The "FTH1P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FTH1P4 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
FTH1P5 | FTH1P7 | FTH1P8 | FTHL17 | FTL | FTLP16 | FTLP2 | FTLP3 | FTLP7 | FTMT | FTO | FTO-IT1 | FTOP1 | FTSJ1 | FTSJ3 | FTX | FUBP1 | FUBP3 | FUCA1 | FUCA2 | Fucosyl GM1 | Fucosyltransferase | FUNDC1 | FUNDC2 | FUNDC2P2 | FUNDC2P3 | FUOM | FURIN | FUS | FUT1 | FUT10 | FUT11 | FUT2 | FUT3 | FUT4 | FUT5 | FUT6 | FUT7 | FUT8 | FUT8-AS1 | FUT9 | FUZ | FXN | FXR1 | FXR2 | FXYD1 | FXYD2 | FXYD3 | FXYD4 | FXYD5 | FXYD6 | FXYD6-FXYD2 | FXYD7 | FYB1 | FYB2 | FYCO1 | FYN | FYTTD1 | FZD1 | FZD10 | FZD10-AS1 | FZD2 | FZD3 | FZD4 | FZD4-DT | FZD5 | FZD6 | FZD7 | FZD8 | FZD9 | FZR1 | G protein-Coupled Inwardly-Rectifying Potassium Channel (GIRK) | G Protein-Coupled Receptor Kinases (GRKs) | G0S2 | G2E3 | G2E3-AS1 | G3BP1 | G3BP2 | G6PC1 | G6PC2 | G6PC3 | G6PD | GA-binding protein | GAA | GAB1 | GAB2 | GAB3 | GAB4 | GABA(A) receptor | GABARAP | GABARAPL1 | GABARAPL2 | GABARAPL3 | GABBR1 | GABBR2 | GABPA | GABPAP | GABPB1 | GABPB1-AS1 | GABPB1-IT1
